P21
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic CNTF-derived peptide marketed for cognitive enhancement and neuroprotection. The case rests entirely on animal studies of memory rescue and reduced tau and amyloid buildup; touted uses in macular degeneration and rare neurodevelopmental disorders remain speculative. There is no human safety data, and boosting neurogenesis carries a theoretical risk of uncontrolled cell growth. Not an approved drug; supply is unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(7)
Rescues cognitive deficits and enhances learning and memory
LowExtensive rodent studies show learning and memory gains; no human trials exist yet.
Reduces abnormal tau hyperphosphorylation and neurofibrillary pathology
LowMultiple rodent studies show reduced tau pathology via a defined mechanism; no human data yet.
Reduces amyloid-beta plaque pathology
LowAnimal studies show mixed results, with amyloid reduction seen only in one lab's model.
Evidence limits
- Evidence Level
- Preclinical Only
All evidence for P021 comes from in vitro and in vivo animal studies. No human clinical trials (Phase 1, 2, or 3) have been published or registered on ClinicalTrials.gov as of March 2026. Preclinical work spans several animal models (3xTg-AD mice, aged Fisher rats, Ts65Dn Down syndrome mice, Cdkl5 KO mice), treatment paradigms (therapeutic, preventive, developmental), and endpoints (cognition, tau/Abeta pathology, neurogenesis, synaptic markers, MRI microstructure), but findings vary by model: the CDKL5 mouse study did not reproduce the BDNF or neuroanatomical benefits reported in other animal models. Long-term administration (up to 18 months in mice) has shown no adverse effects including no weight loss, tumors, or pain. However, the absence of any human data means efficacy and safety in humans remain entirely unestablished.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
No established human safety profile
HighPotential for uncontrolled neurogenesis or cellular proliferation
TheoreticalPotential antibody formation
TheoreticalContraindicated populations (theoretical)
TheoreticalResearch chemical quality and purity concerns
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.